Within the last few decades, numerous advances in the treatment of CLL have been made, including the introduction of novel classes of targeted small molecules such as BCL2 inhibitors, BTK inhibitors, or PI3K inhibitors. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.